A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer
Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs. We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate [...]
Degarelix or Leuprolide – Today’s Question Explored
There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug [...]
Cancergraph, free Quality of Life mobile app launched worldwide today!
Malecare launches Cancergraph, a Quality of Life mobile app recording. It's free on the iOS Apple App store, right now! Go to the App store on your iPhone or Download here https://itunes.apple.com/us/app/cancergraph/id1114343314?mt=8 Android coming in [...]
Prostate Cancer Chemotherapy Is not so bad
Chemotherapy with Taxotere (docetaxel) might not be considered because the side effects are misunderstood. Individual experiences and side effects differ widely from one man to another. n Generally, chemotherapy is not as toxic as we [...]
Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases
We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available [...]
Malecare Founder and Executive Director Darryl Mittendorf Recognized For His Major Contributions To The Prostate Cancer Community By PCRI
Malecare's Founder and Executive Director Darryl Mitteldorf was this years PCRI winner of the Harry Pinchot Award. He is long deserving of this award. I would like to thank Darryl for his years and years [...]